RLYB

+ Watchlist + Portfolio

Rallybio Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $17.00
52-Week Range: $3.67 – $17.57
Market Cap: $88.15M
P/E (TTM): 2.13
EPS (TTM): 7.80
Dividend Yield: —

Advanced Metrics

Price/Book: 1.75
PEG Ratio: —
Return on Equity: 64.86%
Return on Assets: -21.32%
Gross Margin: 0.00%
Operating Margin: -3935.45%
Profit Margin: 7051.24%
Current Ratio: 27.27
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-14.29M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-4.69M

RLYB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$636.00K	$858.00K
Research & Development	$40.69M	$53.54M	$41.51M	$19.60M
Selling, General & Admin	$27.20M	$25.39M	$19.63M	$14.32M
Operating Expenses	$67.88M	$78.93M	$61.13M	$33.92M
Operating Income	-$67.88M	-$78.93M	-$60.50M	-$33.06M
EBITDA	-$67.72M	-$78.78M	-$60.37M	-$32.97M
Pretax Income	-$66.65M	-$74.56M	-$57.77M	-$8.98M
Net Income	-$66.65M	-$74.56M	-$57.77M	-$8.98M
Diluted EPS	-16.72	-14.72	-10.64	-1.59
Diluted Shares	3.98M	5.06M	5.44M	5.63M

RLYB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$56.96M	$24.49M	$13.90M	$31.37M
Current Assets	$179.50M	$114.79M	$67.84M	$61.25M
Total Assets	$180.44M	$115.62M	$68.11M	$62.26M
Current Liabilities	$10.74M	$9.26M	$6.24M	$4.22M
Total Debt	$555.00K	$392.00K	$154.00K	$176.00K
Total Liabilities	$11.12M	$9.44M	$6.45M	$4.30M
Retained Earnings	-$160.68M	-$235.25M	-$293.02M	-$302.00M
Shareholders' Equity	$169.32M	$106.18M	$61.65M	$57.96M
Working Capital	$168.75M	$105.53M	$61.60M	$57.03M

RLYB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$57.28M	-$60.27M	-$49.28M	-$29.81M
Capital Expenditure	-$54.00K	-$12.00K	—	—
Free Cash Flow	-$57.34M	-$60.28M	-$49.28M	-$29.81M
Depreciation & Amortisation	$167.00K	$150.00K	$131.00K	$92.00K
Stock-Based Compensation	$9.50M	$10.92M	$7.99M	$5.31M
Investing Cash Flow	-$112.17M	$27.66M	$33.49M	$47.27M
Financing Cash Flow	$51.08M	$143.00K	$5.20M	$16.00K
Net Change in Cash	-$118.38M	-$32.46M	-$10.59M	$17.47M

RLYB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$212.00K	$212.00K	$212.00K	$222.00K	$212.00K
Research & Development	$5.72M	$6.07M	$4.14M	$3.65M	$2.87M
Selling, General & Admin	$4.16M	$4.20M	$2.99M	$2.98M	$6.07M
Operating Expenses	$9.88M	$10.27M	$7.14M	$6.63M	$8.95M
Operating Income	-$9.67M	-$10.06M	-$6.92M	-$6.41M	-$8.73M
EBITDA	-$9.64M	-$10.03M	-$6.89M	-$6.41M	-$8.73M
Pretax Income	-$9.44M	-$9.42M	$16.02M	-$5.85M	-$8.28M
Net Income	-$9.44M	-$9.70M	$16.02M	-$5.85M	-$8.28M
Diluted EPS	-1.68	-1.76	2.88	—	-1.46
Diluted Shares	5.60M	5.61M	5.63M	—	5.69M

RLYB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$14.78M	$9.45M	$32.12M	$31.37M	$41.30M
Current Assets	$57.38M	$50.27M	$66.63M	$61.25M	$53.49M
Total Assets	$57.98M	$51.00M	$67.66M	$62.26M	$54.47M
Current Liabilities	$3.91M	$5.04M	$4.52M	$4.22M	$4.14M
Total Debt	$116.00K	$58.00K	$198.00K	$176.00K	$154.00K
Total Liabilities	$3.91M	$5.04M	$4.63M	$4.30M	$4.20M
Retained Earnings	-$302.46M	-$312.16M	-$296.15M	-$302.00M	-$310.28M
Shareholders' Equity	$54.07M	$45.96M	$63.03M	$57.96M	$50.28M
Working Capital	$53.47M	$45.23M	$62.11M	$57.03M	$49.35M

RLYB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$10.21M	-$8.38M	-$6.55M	-$4.68M	-$7.98M
Free Cash Flow	-$10.21M	-$8.38M	-$6.55M	-$4.68M	-$7.98M
Depreciation & Amortisation	$28.00K	$26.00K	$35.00K	$3.00K	$3.00K
Stock-Based Compensation	$1.88M	$1.61M	$1.05M	$774.00K	$613.00K
Investing Cash Flow	$11.08M	$3.04M	$29.23M	$3.92M	$17.90M
Financing Cash Flow	$0.00	$10.00K	$0.00	$6.00K	$3.00K
Net Change in Cash	$876.00K	-$5.33M	$22.68M	-$748.00K	$9.93M

Market Snapshot

About

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating development of life-transforming therapies for patients with severe and rare diseases. The company focuses on inhibiting harmful immune responses underlying disease, replacing missing or deficient enzymes or proteins, and modulating dysregulated immune responses. Rallybio has a pipeline of product candidates addressing complement-mediated diseases and genetic disorders.